Overview

Safety and Tolerability Study of FolateImmune in Combination With Cytokines in Patients With Refractory or Metastatic Cancer

Status:
Completed

Trial end date:
2008-06-01

Target enrollment:

Participant gender:

Summary

This is a Phase 1b clinical trial to assess the safety and tolerability of vaccination with EC90 (KLH-FITC) and GPI-0100 (adjuvant) followed by treatment with EC17 (Folate-FITC) in combination with low-dose cytokines (IL-2 and IFN-alpha) in patients with metastatic or refractory cancer.

Phase:

Phase 1

Details

Lead Sponsor:

Endocyte

Treatments:

Folic Acid
Interferon-alpha
Interferons
Interleukin-2
Keyhole-limpet hemocyanin
Vitamin B Complex